Pilot study of gadoxetate disodium-enhanced mri for localized and metastatic prostate cancers

Sarah E. Lochrin, Barış Türkbey, Billel Gasmi, Keith T. Schmidt, Jonathan D. Strope, Cindy H. Chau, Tristan M. Sissung, Douglas K. Price, Lisa M. Cordes, Suzana Markolovic, Bradford J. Wood, Peter A. Pinto, Yolanda McKinney, Joanna H. Shih, Elliot Levy, Ravi A. Madan, William L. Dahut, Peter L. Choyke, Maria J. Merino, William D. FiggScientific 2021 · DOI

Abstract

OATP1B3 is expressed de novo in primary prostate cancer tissue and to a greater degree in prostate cancer metastases. Gadoxetate disodium is a substrate of OATP1B3, and its uptake has been shown to correlate with OATP1B3 expression in other cancers. We aimed to evaluate use of gadoxetate disodium to image prostate cancer and to track its utility as a biomarker. A single center open-label non-randomized pilot study recruited men with (1) localized, and (2) metastatic castration resistant prostate cancer (mCRPC). Gadoxetate disodium-enhanced MRI was performed at four timepoints post-injection. The Wilcoxon signed rank test was used to compare MRI contrast enhancement ratio (CER) pre-injection and post-injection. OATP1B3 expression was evaluated via immunohistochemistry (IHC) and a pharmacogenomic analysis of OATP1B3, NCTP and OATP1B1 was conducted. The mCRPC subgroup (n = 9) demonstrated significant enhancement compared to pre-contrast images at 20-, 40- and 60-min timepoints (p < 0.0078). The localized cancer subgroup (n = 11) demonstrated earlier enhancement compared to the mCRPC group, but no retention over time (p > 0.05). OATP1B3 expression on IHC trended higher contrast enhancement between 20-40 min (p ≤ 0.064) and was associated with contrast enhancement at 60 min (p = 0.0422). OATP1B1 haplotype, with N130D and V174A substitutions, impacted enhancement at 40-60 min (p ≤ 0.038). mCRPC lesions demonstrate enhancement after injection of gadoxetate disodium on MRI and retention over 60 min. As inter-individual variability in OATP1B3 expression and function has both predictive and prognostic significance, gadoxetate disodium has potential as a biomarker in prostate cancer.

Introduction

Prostate cancer often progresses to a "castration-resistant" state, where tumors continue to grow despite suppressed androgen levels. A key mechanism for this survival is the overexpression of the OATP1B3 transporter, which acts as a metabolic scavenger, pulling available androgens from the environment into the cancer cells. While OATP1B3 is a known marker for metastatic progression and therapy resistance, non-invasive methods to monitor its activity have been lacking. This pilot study investigates the repurposing of gadoxetate disodium—an FDA-approved liver MRI contrast agent and OATP1B3 substrate—to visualize this metabolic activity in prostate cancer patients.

Methods

This single-center, open-label pilot study included 20 evaluable patients divided into two cohorts: localized prostate cancer (n=11) and metastatic castration-resistant prostate cancer (mCRPC, n=9).

Patients underwent 3T MRI scans using gadoxetate disodium (Eovist). The Contrast Enhancement Ratio (CER) was measured at 10, 20, 40, and 60 minutes post-injection. To validate the imaging findings, researchers performed immunohistochemistry (IHC) on biopsy samples to quantify OATP1B3 expression. Additionally, a pharmacogenomic analysis was conducted on 51 variants across the SLCO1B3, SLCO1B1, and SLC10A1 genes to determine if genetic background influenced contrast kinetics.

Results and Key Insights

The study revealed a distinct difference in contrast retention between localized and metastatic disease. In localized cancer, the contrast agent peaked early at 10 minutes (p = 0.013) and then washed out, behaving like a standard vascular marker. In contrast, metastatic lesions demonstrated significant uptake and retention throughout the 60-minute observation period.

Figure 5: Contrast enhancement ratio over time (A) and representative MRI images (B) showing retention in mCRPC lesions.

Key findings include:

  • mCRPC Retention: Significant enhancement was observed in the mCRPC group at 20, 40, and 60 minutes (p < 0.0078).
  • Biological Validation: Higher OATP1B3 expression on IHC was significantly associated with higher contrast enhancement at the 60-minute mark (p = 0.0422), confirming that the MRI signal reflects the tumor's metabolic state.
Figure 6: Immunohistochemistry showing OATP1B3 expression in prostate cancer tissue.
  • Genetic Influence: The OATP1B1 haplotype (N130D and V174A substitutions) significantly impacted enhancement at the 40–60 minute intervals (p ≤ 0.038), suggesting that individual genetics play a role in contrast metabolism.

Discussion and Future Directions

By exploiting the fact that metastatic prostate cancer "hijacks" liver-specific transport machinery, this study demonstrates that gadoxetate disodium-enhanced MRI can serve as a functional biomarker. The ability to non-invasively map OATP1B3 activity could provide critical prognostic information and help identify resistance to specific treatments like taxanes.

While limited by a small sample size (n=20), this proof-of-concept trial paves the way for larger prospective studies. Future research should focus on whether this imaging technique can predict treatment response or serve as an early indicator of the transition from localized to aggressive metastatic disease.

Summary updated

Abstract

OATP1B3 is expressed de novo in primary prostate cancer tissue and to a greater degree in prostate cancer metastases. Gadoxetate disodium is a substrate of OATP1B3, and its uptake has been shown to correlate with OATP1B3 expression in other cancers. We aimed to evaluate use of gadoxetate disodium to image prostate cancer and to track its utility as a biomarker. A single center open-label non-randomized pilot study recruited men with (1) localized, and (2) metastatic castration resistant prostate cancer (mCRPC). Gadoxetate disodium-enhanced MRI was performed at four timepoints post-injection. The Wilcoxon signed rank test was used to compare MRI contrast enhancement ratio (CER) pre-injection and post-injection. OATP1B3 expression was evaluated via immunohistochemistry (IHC) and a pharmacogenomic analysis of OATP1B3, NCTP and OATP1B1 was conducted. The mCRPC subgroup (n = 9) demonstrated significant enhancement compared to pre-contrast images at 20-, 40- and 60-min timepoints (p < 0.0078). The localized cancer subgroup (n = 11) demonstrated earlier enhancement compared to the mCRPC group, but no retention over time (p > 0.05). OATP1B3 expression on IHC trended higher contrast enhancement between 20-40 min (p ≤ 0.064) and was associated with contrast enhancement at 60 min (p = 0.0422). OATP1B1 haplotype, with N130D and V174A substitutions, impacted enhancement at 40-60 min (p ≤ 0.038). mCRPC lesions demonstrate enhancement after injection of gadoxetate disodium on MRI and retention over 60 min. As inter-individual variability in OATP1B3 expression and function has both predictive and prognostic significance, gadoxetate disodium has potential as a biomarker in prostate cancer.
BibTeX
@inproceedings{lochrin2021pilot,
  author = {Sarah E. Lochrin and Barış Türkbey and Billel Gasmi and Keith T. Schmidt and Jonathan D. Strope and Cindy H. Chau and Tristan M. Sissung and Douglas K. Price and Lisa M. Cordes and Suzana Markolovic and Bradford J. Wood and Peter A. Pinto and Yolanda McKinney and Joanna H. Shih and Elliot Levy and Ravi A. Madan and William L. Dahut and Peter L. Choyke and Maria J. Merino and William D. Figg},
  title = {{Pilot study of gadoxetate disodium-enhanced mri for localized and metastatic prostate cancers}},
  booktitle = {Scientific},
  year = {2021},
  doi = {10.1038/s41598-021-84960-w},
}
Figure